跳至主要内容
临床试验/NCT06409507
NCT06409507已完成不适用

The Impact of FKBP12 on the Prognosis and Sirolimus Administration in Liver Transplantation Recipients With Hepatocellular Carcinoma: A Single-center Retrospective Cohort Study

First People's Hospital of Hangzhou0 个研究点目标入组 178 人开始时间: 2015年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
178
主要终点
Overall survival

研究概览

简要总结

The study evaluated the protein expression levels of FK506-binding protein 12 (FKBP12) in hepatocellular carcinoma (HCC) and paracancerous tissues using immunohistochemistry (IHC). This study aimed to determine the role of FKBP12 in the outcome of liver transplantation recipients with HCC, especially those exceeding the Milan criteria. In addition, we explored how sirolimus administration affected LT recipients'prognosis depending on different FKBP12 expression, aiming to provide some advice for clinical sirolimus application after LT.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • (1) pathologically confirmed HCC (2) full post-LT follow-up record

排除标准

  • (1)sirolimus treatment less than 30 days or after tumor recurrence (2)died within 90 days (3)underwent multiple-organ transplantation

结局指标

主要结局

Overall survival

时间窗: 2015.1.1-2021.1.1

the length of months between surgery and the last follow-up or death

次要结局

未报告次要终点

研究者

发起方
First People's Hospital of Hangzhou
申办方类型
Other
责任方
Sponsor

相似试验